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CASE REPORTGLUT1-positive recurrent basal cell
carcinoma of basosquamous subtype
detected by positron emission
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Basal cell carcinomas (BCCs) are considered the
most common tumors of thewhite population.1 Even
thoughmetastatic BCCs have an average survival rate
as low as 3.6 years,2 there is a lack of consensus in the
guidelines regarding imaging for BCC follow-up
care.3 Fluorodesoxyglucose (18F-FDG) positron
emission tomographyecomputed tomography
(PET/CT) imaging is established in the follow-up
care of many cancer types but not in BCCs.CASE REPORT
A white woman in her 70s is a melanoma patient
in our clinic. Her 18F-FDG PET/CT scan, conducted
as part of her melanoma follow-up regimen showed
a surprising uptake of 18F-FDG in her chin (Fig 1, A).
The patient had suffered from a partly nodular and
partly morpheaformBCC at the same location 7 years
earlier, which had been excised with narrow tumor
margins. Clinical examination of her chin found a
discrete subcutaneous lump palpable both in the
oral vestibule and transcutaneously at the level of the
former labiomental crease. There was no visible
epidermal manifestation. Ultrasound scan found a
1.6- 3 1.1-cm irregular hypoechogenic lesion corre-
sponding to the palpable tumor (Fig 1, B). Histology
of a deep punch biopsy found a BCC with focal
nodulocystic growth and partly basosquamous dif-
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BerEP4 supporting the finding that the tumor orig-
inated from the basal cell layer. We then performed
surgical excision with tumor-free margins (R0).DISCUSSION
The utility of PET/CT imaging for detecting
primary and recurring BCCs has been investigated
in a recent literature review.4 There is yet no universal
consensus concerning the use of PET/CT imaging, as
a systematic benefit analysis is challenging becauseof
the scarcity of metastasizing BCCs. Because of a lack
of evidence in support of PET/CT imaging for BCCs, it
is currently not thought to be cost effective and is to
be used only if a metastasized BCC is suspected.4
Poor performance of PET/CT imaging for detecting
tumor metastases has been reported.5 The exact
reasons remain elusive. An influence of tumor size
and subtype has been suggested.4,5
Limited attention has been paid to tumor charac-
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Fig 1. A, 18F-FDG PET/CT image shows an increased uptake of 263 MBq 18F-FDG (SUV max,
8.4) in the patient’s chin. B, Ultrasound image shows a hypoechogenic lesion of
10.5 3 16.2 mm in the sagittal plane (color marked in cyan), adjacent to the mandible
(yellow). The corresponding clinical image can be seen below.
Fig 2. A, Histology of the BCC shows characteristic histomorphology, such as peripheral
palisading (black arrow). B, Immunohistochemistry for glucose transporter GLUT1 displays a
focal membranous and cytoplasmatic staining pattern in the center of nodular-cystic areas,
whereas rather classic nodular BCC differentiated parts remained negative for GLUT1.
(A, hematoxylin-eosin stain; B, GLUT1 stain; original magnifications: A, 3100; B, 3200.)
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Literature suggests that there is a significant positive
correlation between 18F-FDGuptake into cancer cells
and glucose transporter-1 (GLUT1) expression, for
example, in lung tumors.6 Metastases of pulmonaryadenocarcinomas with lower GLUT1 expression
show higher false-negative rates in PET/CT imaging
compared with those with higher expression.7 Also,
GLUT1 expression is an emerging marker for poorer
tumor prognosis in oral squamous cell carcinomas.8,9
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BCCs (n = 16) with that in squamous cell carcinomas
(n = 16). The authors described a statistically
significant higher expression of GLUT1 among
squamous cell carcinomas compared with BCCs
and that in BCCs, expression was associated with
squamous metaplastic areas.10
To further assess the involvement of GLUT1
expression in our patient’s basosquamous BCC, we
performed a GLUT1 immunochemistry stain. To our
expectation, this stain showed a focal expression
of GLUT1 in its area of squamous differentiation
(Fig 2, B).
In our view, GLUT1 expression is, in our case,
the most likely reason the recurrent BCC was
incidentally detected by PET/CT imaging and may
suggest that GLUT1 expression holds a more
important role for PET/CT detection of BCCs than
previously assumed. Given that nodular BCCs of
larger sizes than in our case had reportedly been
missed,5 we conclude that tumor size could be
of lesser relevance compared with molecular
properties, such as GLUT1 expression or maybe
other unknown mechanisms. Because GLUT1 seems
to be expressedmore likely in squamous cell tumors,
we think that PET/CT holds most relevance in
detecting metastases of the basosquamous BCC
subtype.
A clear association between enhanced detect-
ability by overexpression of GLUT1 and 18F-FDG
PET/CT imaging for BCCs has yet to be shown in a
larger cohort. However, given that metastatic BCC is
exceedingly rare, this association may be difficult toprove. Alternatively, measuring GLUT1 expression
in histology and drawing suggestions as to tumor
behavior and detectability may be more realistic to
attain.REFERENCES
1. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;
327:794-798.
2. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic
basal cell carcinoma: prognosis dependent on anatomic site
and spread of disease. Eur J Cancer. 2014;50:774-783.
3. Trakatelli M, Morton C, Nagore E, et al. Update of the European
guidelines for basal cell carcinoma management. Eur J
Dermatol. 2014;24:312-329.
4. Duncan JR, Carr D, Kaffenberger BH. The utility of positron
emission tomography with and without computed tomogra-
phy in patients with nonmelanoma skin cancer. J Am Acad
Dermatol. 2016;75:186-196.
5. Fosko SW, Hu W, Cook TF, Lowe VJ. Positron emission
tomography for basal cell carcinoma of the head and neck.
Arch Dermatol. 2003;139:1141-1146.
6. Usuda K, Sagawa M, Aikawa H, et al. Correlation between glucose
transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake
on positron emission tomography in lung cancer. Gen Thorac
Cardiovasc Surg. 2010;58:405-410.
7. Chung JH, Cho KJ, Lee SS, et al. Overexpression of Glut1
in lymphoid follicles correlates with false-positive (18)F-FDG
PET results in lung cancer staging. J Nucl Med. 2004;45:
999-1003.
8. Ohba S, Fujii H, Ito S, et al. Overexpression of GLUT-1 in
the invasion front is associated with depth of oral squamous
cell carcinoma and prognosis. J Oral Pathol Med. 2010;39:74-78.
9. Azad N, Kumari Maurya M, Kar M, et al. Expression of GLUT-1 in
oral squamous cell carcinoma in tobacco and non-tobacco
users. J Oral Biol Craniofac Res. 2016;6:24-30.
10. Abdou AG, Eldien MM, Elsakka D. GLUT-1 Expression in
Cutaneous Basal and Squamous Cell Carcinomas. Int J Surg
Pathol. 2015;23:447-453.
